Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 13

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 13
---
 an exhaustive summary of the material risks facing our business. The following factors could result in harm to our business, reputation, revenue, financial results, and prospects, among other impacts:

Risks Related to Our Financial Position

| ● | Our                                                                                          
 business plan relies upon our ability to obtain additional sources of capital and financing. |

| ● | We                                                                                            
 must raise additional capital to fund our operations in order to continue as a going concern. |

| ● | Our                                                                                         
 limited operating history makes it difficult to evaluate our business and future prospects. |

| ● | We                                                                                            
 are unable to precisely estimate when we will begin to generate significant profit from PPLS. |

| ● | We                                              
 have limited experience operating a laboratory. |

| 2 |

Risks Related to this Offering

| ● | Our                                                                                        
 management will have broad discretion over the use of the net proceeds from this offering. |

| ● | You                                                                                               
 may experience dilution in the net tangible book value per share of the Common Stock issued       
 in this offering or that may be issued upon the exercise of any warrants issued in this offering. |

| ● | Future                                                                                       
 issuances of our Common Stock or rights to purchase Common Stock, could result in additional 
 dilution of the percentage ownership of our stockholders and could cause our stock price     
 to fall.                                                                                     |

| ● | If                                                                                        
 we issue additional securities it could adversely affect the rights of the holders of our 
 Common Stock.                                                                             |

| ● | We                                                                                        
 may not raise the amount of capital we believe is required for our business plans in this 
 offering.                                                                                 |

| ● | Investors                                                                                
 in this offering will not receive a refund in the event that we do not sell an amount of 
 securities sufficient to pursue the business goals outlined in this prospectus.          |

| ● | Purchasers                                                                                         
 of our securities in this offering pursuant to a securities purchase agreement may have additional 
 rights.                                                                                            |

| ● | There                                                                 
 is no public market for the May 2025 Warrants or Pre-Funded Warrants. |

| ● | The                                                           
 May 2025 Warrants in this offering are speculative in nature. |

| ● | Holders                                                                                        
 of warrants purchased in this offering will not have rights of holders of our shares of Common 
 Stock until exercised.                                                                         |

| ● | The                                                                                    
 May 2025 Warrants are not be exercisable until we obtain Warrant Stockholder Approval. |

| ● | If                                                                                         
 we do not